Role of Telomeres and Telomerase in Parkinson's Disease�A New Theranostics?

dc.contributor.authorVellingiri, Balachandar
dc.contributor.authorBalasubramani, Kiruthika
dc.contributor.authorIyer, Mahalaxmi
dc.contributor.authorRaj, Neethu
dc.contributor.authorElangovan, Ajay
dc.contributor.authorSong, Kwonwoo
dc.contributor.authorYeo, Han-Cheol
dc.contributor.authorJayakumar, Namitha
dc.contributor.authorKinoshita, Masako
dc.contributor.authorThangarasu, Ravimanickam
dc.contributor.authorNarayanasamy, Arul
dc.contributor.authorDayem, Ahmed Abdal
dc.contributor.authorPrajapati, Vijay Kumar
dc.contributor.authorGopalakrishnan, Abilash Valsala
dc.contributor.authorCho, Ssang-Goo
dc.date.accessioned2024-01-16T14:23:28Z
dc.date.accessioned2024-08-13T10:34:20Z
dc.date.available2024-01-16T14:23:28Z
dc.date.available2024-08-13T10:34:20Z
dc.date.issued2023-08-21T00:00:00
dc.description.abstractParkinson's disease (PD) is a complex condition that is significantly influenced by oxidative stress and inflammation. It is also suggested that telomere shortening (TS) is regulated by oxidative stress which leads to various diseases including age-related neurodegenerative diseases like PD. Thus, it is anticipated that PD would result in TS of peripheral blood mononuclear cells (PBMCs). Telomeres protect the ends of eukaryotic chromosomes preserving them against fusion and destruction. The TS is a normal process because DNA polymerase is unable to replicate the linear ends of the DNA due to end replication complications and telomerase activity in various cell types counteracts this process. PD is usually observed in the aged population and progresses over time therefore, disparities among telomere length in PBMCs of PD patients are recorded and it is still a question whether it has any useful role. Here, the likelihood of telomere attrition in PD and its implications concerning microglia activation, ageing, oxidative stress, and the significance of telomerase activators are addressed. Also, the possibility of telomeres and telomerase as a diagnostic and therapeutic biomarker in PD is discussed. � 2023 Wiley-VCH GmbH.en_US
dc.identifier.doi10.1002/adbi.202300097
dc.identifier.issn27010198
dc.identifier.urihttps://doi.org/10.1002/adbi.202300097
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/2943
dc.language.isoen_USen_US
dc.publisherJohn Wiley and Sons Incen_US
dc.subjectbiomarkeren_US
dc.subjectmicrogliaen_US
dc.subjectoxidative stressen_US
dc.subjectParkinson's diseaseen_US
dc.subjecttelomerase activatorsen_US
dc.subjecttelomere lengthen_US
dc.titleRole of Telomeres and Telomerase in Parkinson's Disease�A New Theranostics?en_US
dc.title.journalAdvanced Biologyen_US
dc.typeReviewen_US
dc.type.accesstypeOpen Accessen_US

Files